J7201 Alprolix Injection HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS J7201: Factor IX Fc Fusion Protein (Alprolix) Injection, 1 I.U.

HCPCS Level II code J7201 represents the injection of Factor IX Fc fusion protein (recombinant), alprolix, billed per 1 international unit. This code is nationally significant because recombinant factor concentrates are high-cost biologic therapies used for prophylaxis and treatment of bleeding in patients with hemophilia B; accurate coding affects access to therapy and claims processing across public and commercial payers. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what J7201 denotes clinically and operationally, the typical sites where the service is delivered, and the primary payer landscape relevant to coverage and billing. The publication summarizes benchmarks and claim considerations, highlights policy and coverage topics that affect reimbursement and patient access, and provides clinical context about use of recombinant Factor IX products. Data limitations: when specific input items are missing, the report indicates "Data not available in the input." This analysis is written for a national audience and does not make provider recommendations.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7201HCPCS Level IIFactor IXAlprolixBiologic therapyHemophilia BInfusion servicesDrug billing

Billing Code Overview

HCPCS Level II code J7201 describes an injection of Factor IX Fc fusion protein (recombinant), alprolix, measured per 1 international unit (i.u.). This biologic product is used for replacement therapy in patients with hemophilia B or other Factor IX deficiency indications that require factor IX concentrate.

Service type: therapeutic injection / biologic replacement therapy

Typical site of service: hospital outpatient infusion center, physician office, or authorized infusion clinic, where intravenous or subcutaneous administration of recombinant clotting factor products occurs.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric male with moderate to severe hemophilia B (congenital factor IX deficiency) who requires routine prophylactic or episodic replacement therapy with a recombinant factor IX Fc fusion protein (brand name alprolix). The medication is supplied as an injectable concentrate billed per international unit using J7201 (Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u.).

The clinical workflow: the patient presents to an infusion center, hematology clinic, emergency department, or outpatient infusion suite for administration. Pre-infusion steps include review of weight and recent factor IX trough levels, verification of indication (prophylaxis, treatment of bleeding, or perioperative management), informed consent, allergy and infusion history check, and calculation of total units required based on weight and target factor rise. Nursing performs venous access (peripheral IV or implanted port), prepares the reconstituted product under sterile technique, documents lot numbers and expiration, and administers the dose intravenously. Post-infusion monitoring includes observation for hypersensitivity or infusion reactions and documentation of administered units and outcomes in the chart. Typical sites of service are outpatient infusion centers, physician offices (hematology), hospital outpatient departments, ambulatory surgical centers for perioperative dosing, and emergency departments for acute bleeds.

Coding Specifications

Modifier	Description	When to Use

HCPCS J0895: Injection, Deferoxamine Mesylate 500 mg

HCPCS-J1811-INSULIN-FIASP-FOR-INSULIN-PUMP

HCPCS J1811: Insulin (Fiasp) for Insulin Pump, per 50 Units

HCPCS-J7296-LEVONORGESTREL-IUD-KYLEENA-19-5-MG

HCPCS Level II J7296: Levonorgestrel IUD (Kyleena) 19.5 mg

HCPCS-J1943-ARIPIPRAZOLE-LAUROXIL-ARISTADA-INITIO-INJECTION-1MG

HCPCS J1943: Injection, aripiprazole lauroxil (Aristada Initio), 1 mg

HCPCS-J1302-SUTIMLIMAB-INJECTION-10MG

HCPCS J1302: Injection, sutimlimab-jome, 10 mg

HCPCS-J3364-UROKINASE-INJECTION-5000-IU-VIAL

HCPCS J3364: Urokinase Injection, 5,000 IU Vial

HCPCS-J1212-DMSO-50-INJECTION-50ML

HCPCS J1212: Dimethyl Sulfoxide (DMSO) 50% Injection, 50 ml

HCPCS-J1833-ISAVUCONAZONIUM-INJECTION-1MG

HCPCS J1833: Injection, Isavuconazonium, 1 mg

HCPCS-J2596-VASOPRESSIN-INJECTION-LONG-GROVE

HCPCS J2596: Vasopressin Injection (Long Grove), 1 Unit

HCPCS-J7354-CANTHARIDIN-TOPICAL-0-7-SINGLE-UNIT-APPLICATOR

HCPCS J7354: Cantharidin 0.7% Topical Single-Unit Applicator

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology	Hematologists manage hemophilia diagnosis, dosing plans, and long-term replacement therapy.
`364S00000X`	Infusion Therapy	Infusion nurses and infusion centers administer intravenous factor products and monitor patients.
`2080P0207X`	Pediatric Hematology-Oncology	Pediatric specialists manage congenital hemophilia B in infants and children, including dosing and prophylaxis.
`207K00000X`	Internal Medicine	General internists may coordinate outpatient infusions and chronic disease management for adult patients.
`261QM0800X`	Emergency Medicine	Emergency physicians administer factor IX for acute bleeding episodes in the ED and document urgent treatment.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D66`	Hereditary factor VIII deficiency (hemophilia A)	Included as a differential bleeding disorder; factor IX product is not indicated for hemophilia A but differential diagnosis is relevant in bleeding workup.
`D67`	Hereditary factor IX deficiency (hemophilia B)	Primary indication for `alprolix` administration for prophylaxis and treatment of bleeding episodes.
`D68.4`	Acquired coagulation factor deficiency	Relevant when factor IX replacement is used for acquired deficiencies or inhibitors affecting factor IX.
`T45.1X5A`	Adverse effect of anticoagulants, initial encounter	Relevant when factor IX is used to manage bleeding in patients with anticoagulant-related hemorrhage and reversal strategies are considered.
`Z48.01`	Encounter for change or removal of vascular catheter	Relevant when patients receive infusions via implanted ports or central lines and require catheter procedures tied to infusion therapy.
`Z79.01`	Long term (current) use of anticoagulants	Relevant as a medication history code when managing bleeding risk and deciding replacement therapy; helps document concurrent anticoagulation.
`R58`	Hemorrhage, not elsewhere classified	Used for acute bleeding episodes requiring factor IX replacement when a more specific site or cause is not coded.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used for billing infusion administration time when `alprolix` is administered as an IV infusion requiring observation and infusion time in an outpatient or office setting.
`96366`	Intravenous infusion, each additional hour (list separately in addition to code for primary infusion)	Used if administration requires additional monitored infusion time beyond the initial hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Applicable if a subcutaneous or intramuscular supportive injection is given in conjunction, though `alprolix` is IV and this code is rarely used for factor IX.
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs, factor levels, or post-infusion trough testing associated with dosing and monitoring.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, low to moderate complexity	Used for the office visit where dosing is ordered or management is provided for routine prophylaxis or bleed assessment.
`96361`	Intravenous infusion, each additional sequential infusion, up to 1 hour (list separately in addition to primary infusion)	Used when multiple separate infusions are administered in the same encounter (distinct from continuous time).

OpenPayer